AZD9592 monotherapy in vivo in patient-derived xenograft models showed a 30% reduction of tumor in 41% of EGFR mutant NSCLC tumors at 2 mg/kg and a 73% response rate in those treated at 8 mg/kg (38, 39). This evidence concerns the gene EGFR and non-small cell lung carcinoma.